Jefferies Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $39

Benzinga Newsdesk www.benzinga.com Neutral 62.5%

Neg 0% Neu 62.5% Pos 0%

Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $39.